To the Editor: From 2007 to 2009 in Australia, a three-dose course of quadrivalent human papillomavirus (HPV) vaccine was offered to all females aged 12–26 years through school and primary health care settings, with coverage recorded on the National HPV Vaccination Program Register (NHVPR).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Genevieve Chappell for provision of, and advice on, NHVPR data. The NHVPR is funded by the Australian Government. The Victorian Cervical Cytology Registry is funded by the Victorian Government. The NHVPR and Victorian Cervical Cytology Registry are operated by the Victorian Cytology Service.
Julia Brotherton and Dorota Gertig are investigators on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organisation. Julia Brotherton was an investigator on a national HPV prevalence study (2005–2008) that received funding from CSL Biotherapies and GlaxoSmithKline.